Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. πŸ… He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. πŸŽ“ His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. πŸŽ“ Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. πŸ’Š He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. πŸ† This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. πŸ’‘ Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Zhi-Ming Shao | Precision Medicine | Best Researcher Award

Prof. Zhi-Ming Shao, Fudan University Shanghai Cancer Center, China

Prof. Zhi-Ming Shao is a distinguished surgical oncologist and global leader in breast cancer research. A graduate of Shanghai Medical University, he chairs the Department of Breast Surgery at Fudan University Shanghai Cancer Center and directs its Breast Cancer Institute. With extensive postdoctoral experience in the U.S. and over 30 years of academic excellence, Prof. Shao has received numerous national honors, including the Chang Jiang Scholar and China’s Most Beautiful Doctor Award. His groundbreaking research, published in top journals like Nature Genetics and Cancer Cell, has significantly advanced precision oncology and breast cancer therapy worldwide.

Publication Profile

Scopus

Education

Prof. Zhi-Ming Shao began his medical journey at Shanghai Medical University, where he earned his Bachelor of Medicine (1980–1985). Driven by a passion for cancer treatment, he pursued a Residency in Surgical Oncology (1985–1990) at the prestigious Fudan University Shanghai Cancer Center. During this period, he also completed his Doctor of Medicine (M.D.) through a Postgraduate Course in Surgical Oncology (1987–1990) at Shanghai Medical University. His comprehensive education laid a strong foundation for his distinguished career in oncology, combining clinical expertise with academic excellence.

Experience

Prof. Zhi-Ming Shao has undergone extensive professional training and leadership roles in oncology. He began as a Postdoctoral Research Fellow (1990–1991) at Wake Forest University, followed by a role as Research Associate (1991–1995) at the University of Maryland Cancer Center. Returning to China, he became Associate Professor (1996–1998) and then Professor (1998–present) at Fudan University Shanghai Cancer Center. Since 2000, he has chaired the Department of Breast Surgery and became Director of the Breast Cancer Institute (2019–present). He also served as Chairman of the 8th Asian Breast Cancer Association (2010–2012) and is now Honorary Chairman of the China Anti-Cancer Association.

Awards

Prof. Zhi-Ming Shao has received numerous prestigious honors and awards throughout his career. In 1998, he was named one of the first batch of distinguished professors of the Chang Jiang Scholars Program. He was awarded the National Science Fund for Distinguished Young Scholars in 2001 and recognized as a Young and Middle-aged Expert with Outstanding Contributions by the Ministry of Health of China in 2004. His accomplishments include the National Prize of Science and Technology Progress (Grade II) in 2005, the National May Day Labor Medal in 2008, and the Chinese Physician Prize in 2020. He was also honored with the 2023 China’s Most Beautiful Doctor Award.

Research Focus

Prof. Zhi-Ming Shao’s research focuses on breast cancer, particularly in the areas of pathogenesis and treatment strategies. His work explores novel therapeutic approaches, such as targeting specific pathways involved in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, as well as developing targeted imaging agents for improved diagnosis. Prof. Shao has contributed significantly to understanding the molecular mechanisms of breast cancer progression and therapy resistance. His studies involve investigating genetic markers, tumor microenvironment interactions, and new treatment combinations. Overall, his research aims to improve clinical outcomes for breast cancer patients, especially in advanced or resistant cases.

Publication Top Notes

Breast cancer: pathogenesis and treatments

Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4

LINC01235 Promotes Clonal Evolution through DNA Replication Licensing-Induced Chromosomal Instability in Breast Cancer

Pilot Study of Nectin-4–Targeted PET Imaging AgentΒ 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial

The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer

O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-Ξ² signaling to breast cancer progression

Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer

Prognostic value of metabolic signature on 18F-FDGuptake in breast cancer patients after radiotherapy

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer

Michael Harrison | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Michael Harrison | Precision Medicine | Best Researcher Award

Dr. Michael Harrison, UCSF, United States

Dr. Michael Harrison is a pioneering pediatric surgeon and fetal therapy expert. πŸŽ“ He earned his B.A. from Yale (1965) and M.D. from Harvard Medical School (1969), followed by extensive surgical training at Massachusetts General Hospital and fellowships in pediatric surgery. πŸ₯ He joined UCSF in 1978, where he became a Full Professor and founded the Fetal Treatment Center. πŸ‘Ά His groundbreaking work in fetal surgery has earned him numerous accolades, including the Golden Plate Award and presidency of the International Fetal Medicine and Surgery Society. 🌍 Now Professor Emeritus at UCSF, he continues to shape the field of pediatric surgery. ✨

Publication Profile

Scopus

Education

Dr. Michael Harrison πŸŽ“ began his academic journey at Yale University (1961-1965), earning a B.A. before pursuing his M.D. in Medicine at Harvard Medical School (1965-1969) πŸ₯. He completed his surgical residency at Massachusetts General Hospital (1969-1971) and advanced his expertise as a Postdoctoral Fellow in Allergy & Immunology at the National Institute of Allergy and Infectious Disease (1971-1973) 🧬. Returning to Massachusetts General, he served as a Senior Resident (1973-1974) and Chief Resident (1974-1975) πŸ”¬. Further specializing, he completed fellowships in Pediatric Surgery at Rikshospitalet (1975-1976) πŸ‡³πŸ‡΄ and Children’s Hospital of Los Angeles (1976-1978) πŸ‘ΆπŸ©Ί.

Experience

Dr. Michael Harrison πŸ₯ has been a Founding Member of the International Fetal Medicine and Surgery Society (1981-present) πŸ‘Ά and has served as its President at the Annual Meeting (1989, 2006) 🎀. He has contributed as a Committee Member for the Medical Advisory Committee of the American Association of Tissue Banks (1993-present) 🧬 and chaired the Committee on Fetal Therapy at APSA (1994-1996) πŸ₯. A Board Member of the International Society of the Fetus as Patient (1997-present) 🌍, he also consults for the MOMS study (2003-present) 🀰. Since 2010, he has been Vice President of the California Academy of Medicine πŸ“š.

Awards

Dr. Michael Harrison πŸ… has received numerous prestigious honors, including the Golden Plate Award (1982, 1988) πŸ†, the William E. Ladd Medal (2010) πŸ…, and the Lifetime Achievement Award (2011) 🌟 from the International Fetal Medicine and Surgery Society. He was elected to the Institute of Medicine (2009) πŸ“œ and honored with the Denis Browne Gold Medal (2013) 🏡️. As a celebrated lecturer, he has delivered keynote addresses worldwide 🌍, including at the Nobel Minisymposium on Fetal Medicine (1998) 🎀. His groundbreaking contributions in pediatric surgery have earned him global recognition and lasting influence in the field.

Research Focus

Dr. Michael R. Harrison is a pioneering surgeon and researcher in pediatric surgery and fetal therapy πŸ₯πŸ‘Ά. His work focuses on maternal-fetal surgery, particularly for conditions like esophageal atresia and diaphragmatic hernia. He has contributed to the development of magnetic compression anastomosis 🧲 and other innovative minimally invasive surgical devices πŸ”¬. His research advances the treatment of complex congenital disorders and improves outcomes for newborns. With numerous publications, he has significantly impacted pediatric device clinical trials πŸ“Š. Dr. Harrison’s groundbreaking contributions continue to shape the future of pediatric and fetal surgical care 🚼✨.

Publication Top Notes

Pediatric Device Clinical Trials Activity: 1999–2022

Lessons Learned From the First-In-Human Compassionate Use of Connect-EAβ„’ in Ten Patients With Esophageal Atresia

Evaluation of a Magnetic Compression Anastomosis for Jejunoileal Partial Diversion in Rhesus Macaques

Sonographic Predictors of Survival in Fetal Diaphragmatic Hernia

Beyond the gut: spectrum of magnetic surgery devices

The Rearing of Maternal–Fetal Surgery: The Maturation of a Field from Conception to Adulthood

The novel application of an emerging device for salvage of primary repair in high-risk complex esophageal atresia

Esophageal Magnetic Compression Anastomosis in Esophageal Atresia Repair: A PRISMA-Compliant Systematic Review and Comparison with a Novel Approach

An experimental study on long term outcomes after magnetic esophageal compression anastomosis in piglets

Novel device for endoluminal esophageal atresia repair: First-in-human experience

Henryk Mazurek | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Henryk Mazurek | Precision Medicine | Best Researcher Award

Prof. Henryk Mazurek, National Tuberculosis and Lung Diseases Institute, Department of Pneumonology and Cystic Fibrosis, Poland

Prof. Henryk Mazurek is a distinguished pulmonologist, allergologist, and pediatrician specializing in pediatric pulmonology and respiratory diseases. He serves as the Head of the Department of Pneumonology and Cystic Fibrosis at the National Tuberculosis and Lung Diseases Institute, Poland πŸ‡΅πŸ‡±. With over 60 original research articles and extensive contributions to medical literature πŸ“š, he has significantly advanced the understanding of chronic respiratory diseases, asthma, and cystic fibrosis. A member of esteemed scientific societies 🌍, he actively collaborates internationally and leads impactful research projects. His work in AI-assisted diagnostics and pulmonary care is shaping the future of respiratory medicine. πŸš€

Publication Profile

Scopus

Professional Background

Professor Henryk Mazurek is a distinguished pulmonary disease specialist, allergologist, pediatrician, and pediatric pulmonology expert 🩺. He completed postgraduate studies in respiratory pathophysiology in France πŸ‡«πŸ‡· and holds the title of Full Professor in medical and health sciences πŸŽ“. As an academic, he teaches nursing and postgraduate medical training in pediatrics, allergology, and lung diseases. He has authored and co-authored over 60 original articles, 100+ textbook chapters, and numerous scientific publications πŸ“š. A sought-after lecturer, he shares his expertise at medical conferences, educating physicians and healthcare professionals worldwide 🌍.

Memberships

Prof. Henryk Mazurek is an esteemed member of several prestigious scientific organizations, fostering international collaboration in respiratory medicine 🌍🫁. He holds a combined membership in the European Respiratory Society (ERS) / Polish Respiratory Society, along with memberships in the Polish Society of Allergology and the Polish Society of Pediatric Pulmonology, where he is an honorary member πŸŽ–οΈ. For many years, he contributed to the Scientific Council of the Institute of Tuberculosis and Lung Diseases in Warsaw πŸ₯. Additionally, he served on the Main Boards of the Polish Society of Allergology (2015-2021) and the Polish Society of Cystic Fibrosis (2014-2018) πŸ“š.

Industry Projects

Prof. Henryk Mazurek has actively contributed to over 50 industry-sponsored clinical trials, showcasing his expertise in applied research πŸ”¬. His consultancy work plays a crucial role in bridging academic research with real-world healthcare applications, particularly in advancing treatment strategies for cystic fibrosis 🫁. Through his collaborations with pharmaceutical and medical device companies πŸ’ŠπŸ©Ί, he has successfully translated research findings into clinical practice, improving patient outcomes. His dedication to innovation and evidence-based solutions continues to shape the future of respiratory medicine, reinforcing his impact on both academia and industry. 🌍

Research Focus

Prof. Henryk Mazurek’s research primarily focuses on respiratory diseases 🫁, particularly in cystic fibrosis 🧬, pediatric pulmonology πŸ‘Ά, and ventilator-associated pneumonia πŸ₯. His work explores innovative AI-facilitated home monitoring πŸ€– for cystic fibrosis, childhood asthma treatments 🌬️, and the effects of medications like Gabapentin on post-operative pain πŸ’Š. He has also studied risk factors for pneumonia 🦠 and strategies for its prevention in ventilated patients. His expertise lies in pulmonary infections, inflammatory biomarkers, and personalized medicine πŸ§‘β€βš•οΈ. His contributions significantly impact respiratory healthcare, enhancing diagnostic and therapeutic approaches for both pediatric and adult patients.

Publication Top Notes

AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations

Childhood asthma treatment based on indirect hyperresponsiveness test: Randomized controlled trial

The Effects of Gabapentin on Post-Operative Pain and Anxiety, Morphine Consumption and Patient Satisfaction in Paediatric Patients Following the Ravitch Procedureβ€”A Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial

Risk Factors and Protective Factors against Ventilator-Associated Pneumoniaβ€”A Single-Center Mixed Prospective and Retrospective Cohort Study

Automatic continuous control of cuff pressure and subglottic secretion suction used together to prevent pneumonia in ventilated patientsβ€”a retrospective and prospective cohort study

Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6